These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35355425)

  • 1. The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity.
    Di Lisi D; Madaudo C; Alagna G; Santoro M; Rossetto L; Siragusa S; Novo G
    ESC Heart Fail; 2022 Jun; 9(3):1914-1919. PubMed ID: 35355425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The added value of the HFA/ICOS score in the prediction of chemotherapy-related cardiac dysfunction in breast cancer.
    Di Lisi D; Madaudo C; Faro DC; Rossetto L; Triolo OF; Losi V; Galassi AR; Monte IP; Novo G
    J Cardiovasc Med (Hagerstown); 2024 Mar; 25(3):218-224. PubMed ID: 38305134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: The HFA/ICOS risk tool in real-world practice.
    Tini G; Cuomo A; Battistoni A; Sarocchi M; Mercurio V; Ameri P; Volpe M; Porto I; Tocchetti CG; Spallarossa P
    Int J Cardiol; 2022 Feb; 349():134-137. PubMed ID: 34848212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score.
    Fernando F; Andres MS; Claudiani S; Kermani NZ; Ceccarelli G; Innes AJ; Khan A; Rosen SD; Apperley JF; Lyon AR; Milojkovic D
    Cardiooncology; 2024 Jul; 10(1):42. PubMed ID: 39010172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular adverse events and prognosis in patients with haematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO Registry insights.
    Shibata T; Nohara S; Morikawa N; Shibao K; Ito S; Shibata R; Toh U; Nagafuji K; Fukami K; Fukumoto Y
    Eur J Prev Cardiol; 2023 Dec; 30(18):1941-1949. PubMed ID: 37352112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score.
    Rivero-Santana B; Saldaña-García J; Caro-Codón J; Zamora P; Moliner P; Martínez Monzonis A; Zatarain E; Álvarez-Ortega C; Gómez-Prieto P; Pernas S; Rodriguez I; Buño Soto A; Cadenas R; Palacios Ozores P; Pérez Ramírez S; Merino Salvador M; Valbuena S; Fernández Gasso L; Juárez V; Severo A; Terol B; de Soto Álvarez T; Rodríguez O; Brion M; González-Costello J; Canales Albendea M; González-Juanatey JR; Moreno R; López-Sendón J; López-Fernández T
    Eur Heart J; 2024 Aug; ():. PubMed ID: 39106857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience.
    Novo G; Di Lisi D; Bronte E; Macaione F; Accurso V; Badalamenti G; Rinaldi G; Siragusa S; Novo S; Russo A
    Oncology; 2020; 98(7):445-451. PubMed ID: 32348984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.
    Caocci G; Mulas O; Abruzzese E; Luciano L; Iurlo A; Attolico I; Castagnetti F; Galimberti S; Sgherza N; Bonifacio M; Annunziata M; Gozzini A; Orlandi EM; Stagno F; Binotto G; Pregno P; Fozza C; Trawinska MM; De Gregorio F; Cattaneo D; Albano F; Gugliotta G; Baratè C; Scaffidi L; Elena C; Pirillo F; Scalzulli E; La Nasa G; Foà R; Breccia M
    Hematol Oncol; 2019 Aug; 37(3):296-302. PubMed ID: 30892724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
    Mulas O; Abruzzese E; Luciano L; Iurlo A; Attolico I; Castagnetti F; Galimberti S; Bonifacio M; Annunziata M; Gozzini A; Orlandi EM; Stagno F; Binotto G; Pregno P; Fozza C; Loi M; Trawinska MM; De Gregorio F; Cattaneo D; Albano F; Iezza M; Baratè C; Scaffidi L; Elena C; Giai V; Scalzulli E; Breccia M; La Nasa G; Caocci G
    Ann Hematol; 2024 Feb; 103(2):427-436. PubMed ID: 38012435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment.
    Breccia M; Molica M; Zacheo I; Serrao A; Alimena G
    Ann Hematol; 2015 Mar; 94(3):393-7. PubMed ID: 25304102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors.
    Casavecchia G; Spinosa G; De Gennaro L; Zicchino S; Gravina M; Magnesa M; Di Biase M; Brunetti ND
    Acta Cardiol; 2022 Apr; 77(2):130-135. PubMed ID: 33685352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
    Jain P; Kantarjian H; Boddu PC; Nogueras-González GM; Verstovsek S; Garcia-Manero G; Borthakur G; Sasaki K; Kadia TM; Sam P; Ahaneku H; O'Brien S; Estrov Z; Ravandi F; Jabbour E; Cortes JE
    Blood Adv; 2019 Mar; 3(6):851-861. PubMed ID: 30885996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer.
    Battisti NML; Andres MS; Lee KA; Ramalingam S; Nash T; Mappouridou S; Senthivel N; Asavisanu K; Obeid M; Tripodaki ES; Angelis V; Fleming E; Goode EF; John S; Rosen SD; Allen M; Stanway S; Lyon AR; Ring A
    Breast Cancer Res Treat; 2021 Jul; 188(1):149-163. PubMed ID: 33818652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Cardiovascular Adverse Events of Long-term Treatment with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Report from the Nagasaki CML Study Group.
    Chiwata M; Itonaga H; Sato S; Hashimoto M; Fujioka M; Kasai S; Sakamoto H; Toriyama E; Nakashima J; Kamijo R; Kitanosono H; Kobayashi Y; Horai M; Taguchi M; Matsuo M; Makiyama J; Takasaki Y; Matsuo E; Horio K; Ando K; Sawayama Y; Taguchi J; Kawaguchi Y; Tsushima H; Imanishi D; Imaizumi Y; Yoshida S; Jo T; Nonaka H; Moriuchi Y; Nagai K; Yokota KI; Hata T; Miyazaki Y
    Intern Med; 2021 Jul; 60(14):2207-2216. PubMed ID: 33612681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.
    Lyon AR; Dent S; Stanway S; Earl H; Brezden-Masley C; Cohen-Solal A; Tocchetti CG; Moslehi JJ; Groarke JD; Bergler-Klein J; Khoo V; Tan LL; Anker MS; von Haehling S; Maack C; Pudil R; Barac A; Thavendiranathan P; Ky B; Neilan TG; Belenkov Y; Rosen SD; Iakobishvili Z; Sverdlov AL; Hajjar LA; Macedo AVS; Manisty C; Ciardiello F; Farmakis D; de Boer RA; Skouri H; Suter TM; Cardinale D; Witteles RM; Fradley MG; Herrmann J; Cornell RF; Wechelaker A; Mauro MJ; Milojkovic D; de Lavallade H; Ruschitzka F; Coats AJS; Seferovic PM; Chioncel O; Thum T; Bauersachs J; Andres MS; Wright DJ; López-Fernández T; Plummer C; Lenihan D
    Eur J Heart Fail; 2020 Nov; 22(11):1945-1960. PubMed ID: 32463967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC).
    Čelutkienė J; Pudil R; López-Fernández T; Grapsa J; Nihoyannopoulos P; Bergler-Klein J; Cohen-Solal A; Farmakis D; Tocchetti CG; von Haehling S; Barberis V; Flachskampf FA; Čeponienė I; Haegler-Laube E; Suter T; Lapinskas T; Prasad S; de Boer RA; Wechalekar K; Anker MS; Iakobishvili Z; Bucciarelli-Ducci C; Schulz-Menger J; Cosyns B; Gaemperli O; Belenkov Y; Hulot JS; Galderisi M; Lancellotti P; Bax J; Marwick TH; Chioncel O; Jaarsma T; Mullens W; Piepoli M; Thum T; Heymans S; Mueller C; Moura B; Ruschitzka F; Zamorano JL; Rosano G; Coats AJS; Asteggiano R; Seferovic P; Edvardsen T; Lyon AR
    Eur J Heart Fail; 2020 Sep; 22(9):1504-1524. PubMed ID: 32621569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
    Lipton JH; Chuah C; Guerci-Bresler A; Rosti G; Simpson D; Assouline S; Etienne G; Nicolini FE; le Coutre P; Clark RE; Stenke L; Andorsky D; Oehler V; Lustgarten S; Rivera VM; Clackson T; Haluska FG; Baccarani M; Cortes JE; Guilhot F; Hochhaus A; Hughes T; Kantarjian HM; Shah NP; Talpaz M; Deininger MW;
    Lancet Oncol; 2016 May; 17(5):612-21. PubMed ID: 27083332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease.
    Leong D; Aghel N; Hillis C; Siegal D; Karampatos S; Rangarajan S; Pond G; Seow H
    Heart; 2021 Apr; 107(8):667-673. PubMed ID: 33419879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heart Failure Association-International Cardio-Oncology Society Risk Score Validation in HER2-Positive Breast Cancer.
    Cronin M; Crowley A; Davey MG; Ryan P; Abdelshafy M; Elkoumy A; Elzomor H; Arsang-Jang S; Ganly S; Nash P; Crowley J; Sharif F; Simpkin A; Lowery A; Wijns W; Kerin M; Soliman O
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36835818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies.
    Singh AP; Glennon MS; Umbarkar P; Gupte M; Galindo CL; Zhang Q; Force T; Becker JR; Lal H
    Cardiovasc Res; 2019 Apr; 115(5):966-977. PubMed ID: 30629146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.